Cellectar Biosciences (CLRB) EPS (Basic) Growth (5y) (2015 - 2026)
Cellectar Biosciences (CLRB) EPS (Basic) Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.97 Bn | 132.12 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.64 Bn | 78.64 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.55 Bn | 60.37 Bn | 1.37 Bn |
| 4 | Moderna | 61.26 Bn | 56.12 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.30 Bn | 37.20 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.66 Bn | 28.35 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.68 Bn | 10.29 Bn | 668.28 Mn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - |
| 10 | Cellectar Biosciences | 6.72 Mn | 6.72 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 37.19% |
| Dec 31, 2025 | 47.75% |
| Sep 30, 2025 | 49.11% |
| Jun 30, 2025 | 45.06% |
| Mar 31, 2025 | 49.62% |
| Dec 31, 2024 | 5.71% |
| Sep 30, 2024 | 38.82% |
| Jun 30, 2024 | 40.98% |
| Mar 31, 2024 | 45.73% |
| Dec 31, 2023 | 38.21% |
| Sep 30, 2023 | 44.68% |
| Jun 30, 2023 | 48.77% |
| Mar 31, 2023 | 47.94% |
| Dec 31, 2022 | 21.98% |
| Sep 30, 2022 | 44.85% |
| Jun 30, 2022 | 44.87% |
| Mar 31, 2022 | 46.73% |
| Dec 31, 2021 | 54.74% |
| Sep 30, 2021 | 53.19% |
| Jun 30, 2021 | 53.12% |